Glaukos Corp

GKOS

Company Profile

  • Business description

    Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

  • Contact

    One Glaukos Way
    Aliso ViejoCA92656
    USA

    T: +1 949 367-9600

    E: [email protected]

    https://www.glaukos.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2025

    Employees

    995

Stocks News & Analysis

stocks

Progress in UK expansion for undervalued ASX share

Guidance reaffirmed and UK implementation on track.
stocks

The sectors set to soar on government spending

Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks

Chart of the Week: How private companies are reshaping public markets

Our latest take from the US Manager Research team.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,094.9013.40-0.15%
CAC 408,074.236.700.08%
DAX 4024,049.74100.630.42%
Dow JONES (US)47,311.00225.760.48%
FTSE 1009,777.0862.120.64%
HKSE26,361.40425.991.64%
NASDAQ23,499.80151.160.65%
Nikkei 22550,920.14707.871.41%
NZX 50 Index13,576.8144.17-0.32%
S&P 5006,796.2924.740.37%
S&P/ASX 2008,823.9012.90-0.15%
SSE Composite Index4,004.2535.000.88%

Market Movers